LEO Pharma to Showcase New Data Highlighting the Burden and Unmet Needs in Chronic Hand Eczema at ESCD 2026 in Copenhagen
New data show that chronic hand eczema can disrupt working lives and school days, with many patients reporting sick leave from work and worsening of symptoms during everyday activities.1
Findings from the DELTA FORCE and DELTA TEEN phase 3 studies highlight the heavy burden of chronic hand eczema across the life course – from impaired work productivity in adults to an impact on school life in adolescents.1,2
LEO Pharma A/S, a global leader in medical dermatology, today announces its scientific program for the European Society of Contact Dermatitis (ESCD) Congress 2026, taking place in Copenhagen, Denmark. At the congress, hosted on LEO Pharma’s home ground, the company will present new data highlighting the burden, symptom severity and ongoing unmet needs of people living with chronic hand eczema (CHE).1-5
LEO Pharma will present multiple posters covering patient‑reported outcomes, disease burden in both adolescents and adults, and emerging insights into the skin microbiome in chronic hand eczema, reflecting the company’s continued investment in advancing understanding of this debilitating disease across the life course.1-5
